Sarepta Therapeutics logo

Sarepta Therapeutics

SRPT | NASDAQ
Chart Builder DCF Calculator
$15.13
-$0.94 (-5.85%)
At close: Nov 16, 2026, 4:00 PM ET
$15.20
+$0.07 (+0.46%)
After-hours: Nov 16, 2026, 7:30 PM ET
-5.85%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
36.7
Fundamentals Weak
Market Sentiment Neutral
Moat Narrow
Sector Rank #624/1021 (Top 61%)

Key Statistics

Market Data

Market Cap $1.62B
1D Range
15.06 16.00
52W Range
14.86 23.83

Valuation (TTM)

PE -11.04
PB 1.06
EV/EBITDA 11.58

Valuation (NTM)

Forward PE 6.25
Forward PEG -1.17
Price Target $19.50
Loading financial charts...

Profile

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene ther...

Sector Healthcare
Industry Biotechnology
Employees 835
IPO Date Jun 4, 1997
Fiscal Year January - December

Latest News

Sarepta Therapeutics Sees Transformational 2027 as Rare Disease Programs Advance

7 days ago · marketbeat.com

Sarepta Therapeutics Sees Transformational 2027 as Rare Disease Programs Advance
Sarepta Therapeutics, Inc. (SRPT) Q3 2026 Earnings Call Transcript

9 days ago · seekingalpha.com

Sarepta Therapeutics, Inc. (SRPT) Q3 2026 Earnings Call Transcript
SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales Decline

11 days ago · zacks.com

SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales Decline
Sarepta Therapeutics Q3 Earnings Call Highlights

11 days ago · marketbeat.com

Sarepta Therapeutics Q3 Earnings Call Highlights
Compared to Estimates, Sarepta Therapeutics (SRPT) Q3 Earnings: A Look at Key Metrics

11 days ago · zacks.com

Compared to Estimates, Sarepta Therapeutics (SRPT) Q3 Earnings: A Look at Key Metrics
Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?

19 days ago · zacks.com

Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?
Sarepta Therapeutics to Present at Upcoming Investor Conferences

21 days ago · businesswire.com

Sarepta Therapeutics to Present at Upcoming Investor Conferences
Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results

26 days ago · businesswire.com

Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting

1 month ago · businesswire.com

Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting
Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner'

1 month ago · benzinga.com

Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner'

Earnings

Latest Earnings
Nov 5, 2026
EPS
$0.13
Beat +64.60%
REV
$381.35M
Beat +8.28%
Next Earnings
Feb 24, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
11
Consensus
Hold
Price Target
$20.00
Upside
+32.19%
Buy (5)
Hold (3)
Sell (3)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.